Pricing Log in Create free account
Saturday 17 October 2026 Export MOLN’s income statement to Excel — free account

Molecular Partners AG Sponsored ADR

MOLN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 98.9%, EPS grew 34.3% and free cash flow grew 23.8%, each against the same quarter a year earlier.

3.56 0.09 −2.47%
Market cap
$143.5M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
2.72
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 1.41%

Capital & Financial Ratios $m

Market Cap 143.47
Revenue 5.65
Net Income (63.15)
Free Cash Flow (57.35)
Net Debt (85.95)
Current Ratio 7.27 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (2.68) (negative: loss-making)
P/S ratio 24.43 (above 10: high)
P/B ratio 1.86
Past 5Y EPS Growth —
This Y EPS Growth 19.06% (at or above 15%: strong)
Next Y EPS Growth 11.30%
Next Y revenue growth 26.72% (at or above 10%: strong)
Next 5Y EPS Growth 9.66%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.2×, against a ten-year median of −0.2×; over the ten years it ranged from −12.3× in 2023 to 69.2× in 2022.
P/S against its own 10 years 57.69%
10-year low 10-year high
P/B against its own 10 years 76.36%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 208 170 112 86
Receivables 2 3 2 2
Inventory — — — —
Other 4 3 2 3
214 175 117 90
2023 2024 2025 Q'26
Payables 1 2 2 2
ST’ Debt — — — —
Other 5 — — —
16 12 13 12

Compound Annual Growth %

10y 5y 3y
Sales — (23.12%) (19.12%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (3.25%) (26.72%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 3 2 1 0 6
’23 3 0 3 1 8
’22 187 12 2 3 199
’21 1 4 4 2 11
’20 — — — — 10
’19 — — — — 21
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (14) — — —
’25 (19) (18) (14) (12) (62)
’24 (19) (17) (17) (14) (67)
’23 (18) (15) (16) (17) (66)
’22 177 (21) (19) (15) 124
’21 (33) (25) (78) (21) (100)
’20 — — — (31) (31)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (14) — — —
’25 (19) (18) (14) (12) (63)
’24 (20) (17) (17) (14) (68)
’23 (18) (16) (16) (17) (67)
’22 177 (21) (19) (15) 123
’21 (33) (25) (79) (21) (101)
’20 — — — (32) (33)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.45) (0.44) — — —
’25 (0.50) (0.67) (0.41) (0.41) (1.99)
’24 (0.39) (0.51) (0.57) (0.34) (1.81)
’23 (0.49) (0.55) (0.40) (0.68) (2.10)
’22 5.00 (0.15) (0.42) (0.52) 3.71
’21 (0.63) (0.61) (0.41) (0.60) (2.25)
’20 — — — — (2.68)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 9.57 5.50 3.53 3.32 3.36

Analyst estimates 2026–2028

Powerpack
High — — — — — 21.33 32.04 7.36 12.70 5.91
People
People Employees — — — — 152 163 175 168 158 134
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.07 0.07 1.14 0.05 0.04 0.00
Income, $m
Income, $m Revenue 23 20 11 21 10 11 199 8 6 —
Gross margin, % 0.00 94.28 0.00 0.00 (500.12) (471.23) 73.23 (593.15) (877.95) 0.00
EBT (18) (26) (38) (37) (67) (70) 123 (69) (61) (74)
EBT margin, % (80.78) (127.05) (357.66) (177.95) (671.82) (653.91) 62.16 (880.71) (1,087.35) 0.00
Net income (18) 0 (38) (37) (67) (70) 123 (69) (61) (74)
Depreciation 1 1 1 3 3 3 3 3 3 3
Per share, $
Per share, $ Revenue 1.11 0.84 0.50 0.98 0.40 0.34 6.12 0.24 0.17 0.00
Earnings (0.89) (1.24) (1.79) (1.74) (2.68) (2.25) 3.80 (2.10) (1.81) (1.99)
Cash flow (1.68) (1.66) (2.01) 0.01 (1.24) (3.21) 3.83 (2.01) (1.98) (1.66)
Capex 0.00 0.00 0.00 0.00 (0.07) (0.05) (0.05) (0.03) (0.02) (0.02)
Free cash flow (1.68) (1.66) (2.01) 0.01 (1.31) (3.26) 3.78 (2.03) (2.00) (1.68)
Book value 6.52 4.91 4.42 2.61 4.57 3.79 7.59 6.00 4.73 2.60
Shares, m 20 24 21 21 25 31 32 33 34 37
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 1.59 0.00 0.00 —
P/S 0.00 0.00 0.00 0.00 0.00 58.15 1.13 17.43 28.64 —
P/B 5.47 5.47 5.47 5.47 5.47 5.25 0.91 0.70 1.00 —
EV/Sales 0.00 0.00 0.00 0.00 0.00 44.45 (0.19) (9.12) (1.43) —
EV/FCF 0.00 0.00 0.00 0.00 0.00 (3.02) (0.33) 1.07 0.12 —
Cash, $m
Cash, $m Operating cash flow (34) (40) (43) 0 (31) (100) 124 (66) (67) (62)
Capex (1) (1) (1) (2) (2) (1) (1) (1) (1) (1)
Free cash flow (34) (40) (43) 0 (33) (101) 123 (67) (68) (63)
Balance, $m
Balance, $m Working capital 163 131 119 74 128 128 249 198 163 104
Total debt — — — 3 8 7 5 — — —
Net debt (177) (144) (101) (95) (185) (145) (261) (208) (170) (112)
Shareholders’ equity 133 119 94 56 114 117 246 197 161 97
Returns, %
Returns, % ROA (11.13) (28.75) (22.31) (28.07) (43.44) (35.88) 53.26 (27.85) (30.62) (49.07)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (14.47) (20.57) (35.54) (50.08) (78.68) (60.23) 67.89 (31.17) (34.35) (57.72)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Molecular Partners AG Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NBP NovaBridge Biosciences $149.6M — (loss-making) — (loss-making) −88.54% (below 0%: shrinking) n/m +34.25% (above 0%: growing) 100.00% 0.00% Compare
CNTN Canton Strategic Holdings, Inc. $149.0M 9.0× — — n/m −600.39% (below 0%: shrinking) 100.00% (80.37%) Compare
CDXS Codexis, Inc. $148.9M — (loss-making) — (loss-making) −2.69% (below 0%: shrinking) n/m +48.60% (above 0%: growing) 76.45% (75.29%) Compare
MENS Jyong Biotech Ltd. $147.0M — — — — — — — Compare
MSLE Satellos Bioscience Inc. $145.1M — (loss-making) — — n/m −65.66% (below 0%: shrinking) 99.26% 0.00% Compare
MOLN Molecular Partners AG Sponsored ADR $143.5M — (loss-making) — (loss-making) −98.86% (below 0%: shrinking) n/m +23.77% (above 0%: growing) 0.00% 0.00%
TARA Protara Therapeutics, Inc. $141.8M — (loss-making) — — n/m −28.10% (below 0%: shrinking) 0.00% 0.00% Compare
ALXO ALX Oncology Holdings Inc. $138.3M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m +31.65% (above 0%: growing) 0.00% 0.00% Compare
NKTX Nkarta, Inc. $138.2M — (loss-making) — — n/m −29.19% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $146.1M — — −88.54% — −28.10% 76.45% 0.00%

All 614 Biotechnology stocks →

Molecular Partners AG Sponsored ADR (MOLN) key facts

  • Molecular Partners AG Sponsored ADR (MOLN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, MOLN traded at $3.56, a market capitalization of $143.5 million.
  • Return on equity was −57.7% and debt-to-equity 0.00.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 2.72 (grey zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.

Molecular Partners AG Sponsored ADR (MOLN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MOLN · Data as of Dec 31, 2024 · For information only; not investment advice. · © 2026 stockrow.com